1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
3. Yoshimura T, Shimoyama T, Tanaka M, Sasaki Y, Fukuda S, Munakata A. Gastric mucosal inflammation and epithelial cell turnover are associated with gastric cancer in patients with
Helicobacter pylori infection. J Clin Pathol 2000;53:532–536.
4. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31–49.
5. Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 1990;50:4737–4740.
6. Kim N, Park YS, Cho SI, et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease. Helicobacter 2008;13:245–255.
9. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735–6740.
10. Meining A, Morgner A, Miehlke S, Bayerdörffer E, Stolte M. Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach: a reality or merely an hypothesis? Best Pract Res Clin Gastroenterol 2001;15:983–998.
11. Uemura N, Okamoto S, Yamamoto S, et al.
Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784–789.
13. Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 2002;16:1249–1259.
15. de Vries AC, Kuipers EJ. Epidemiology of premalignant gastric lesions: implications for the development of screening and surveillance strategies. Helicobacter 2007;12 Suppl 2:22–31.
16. Atherton JC. The clinical relevance of strain types of
Helicobacter pylori. Gut 1997;40:701–703.
17. Kuipers EJ, Pérez-Pérez GI, Meuwissen SG, Blaser MJ.
Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst 1995;87:1777–1780.
18. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003;125:1636–1644.
19. Basso D, Zambon CF, Letley DP, et al. Clinical relevance of
Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology 2008;135:91–99.
20. Nogueira C, Figueiredo C, Carneiro F, et al.
Helicobacter pylori genotypes may determine gastric histopathology. Am J Pathol 2001;158:647–654.
21. Almeida R, Silva E, Santos-Silva F, et al. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol 2003;199:36–40.
23. Filipe MI, Barbatis C, Sandey A, Ma J. Expression of intestinal mucin antigens in the gastric epithelium and its relationship with malignancy. Hum Pathol 1988;19:19–26.
25. Reis CA, David L, Correa P, et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res 1999;59:1003–1007.
27. Hu GY, Yu BP, Dong WG, et al. Expression of TFF2 and
Helicobacter pylori infection in carcinogenesis of gastric mucosa. World J Gastroenterol 2003;9:910–914.
28. Gutiérrez-González L, Wright NA. Biology of intestinal metaplasia in 2008: more than a simple phenotypic alteration. Dig Liver Dis 2008;40:510–522.
29. Kim N, Park RY, Cho SI, et al.
Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up. J Clin Gastroenterol 2008;42:448–454.
31. Lofgren JL, Whary MT, Ge Z, et al. Lack of commensal flora in
Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology 2011;140:210–220.
32. Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut 2018;67:226–236.
33. Song M, Camargo MC, Weinstein SJ, et al. Serum pepsinogen 1 and anti-
Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males. Aliment Pharmacol Ther 2018;47:494–503.
35. Leja M, Lapina S, Polaka I, et al. Pepsinogen testing for evaluation of the success of
Helicobacter pylori eradication at 4 weeks after completion of therapy. Medicina (Kaunas) 2014;50:8–13.
36. Suzuki H, Masaoka T, Hosoda H, et al. Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio--a possible novel and non-invasive marker for gastric atrophy. Hepatogastroenterology 2004;51:1249–1254.
39. Gao Y, Zhang K, Xi H, et al. Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis. Oncotarget 2017;8:6330–6340.
41. Kim JS, Kim BW. Pathophysiology and epidemiology of intestinal metaplasia. Korean J Helicobacter Up Gastrointest Res 2013;13:73–77.
42. de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008;134:945–952.
44. González CA, Sanz-Anquela JM, Companioni O, et al. Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study. J Gastroenterol Hepatol 2016;31:953–958.
45. Asaka M, Sugiyama T, Nobuta A, Kato M, Takeda H, Graham DY. Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. Helicobacter 2001;6:294–299.
46. Sakaki N, Kozawa H, Egawa N, Tu Y, Sanaka M. Ten-year prospective follow-up study on the relationship between
Helicobacter pylori infection and progression of atrophic gastritis, particularly assessed by endoscopic findings. Aliment Pharmacol Ther 2002;16 Suppl 2:198–203.
47. Figueiredo C, Van Doorn LJ, Nogueira C, et al.
Helicobacter pylori genotypes are associated with clinical outcome in Portuguese patients and show a high prevalence of infections with multiple strains. Scand J Gastroenterol 2001;36:128–135.
48. Figueiredo C, Machado JC, Pharoah P, et al.
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002;94:1680–1687.
49. Meining AG, Bayerdörffer E, Stolte M.
Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of gastric carcinoma patients. Eur J Gastroenterol Hepatol 1999;11:717–720.
50. Machado JC, Pharoah P, Sousa S, et al. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 2001;121:823–829.
51. Peleteiro B, Lunet N, Figueiredo C, Carneiro F, David L, Barros H. Smoking,
Helicobacter pylori virulence, and type of intestinal metaplasia in Portuguese males. Cancer Epidemiol Biomarkers Prev 2007;16:322–326.
52. Bergin IL, Sheppard BJ, Fox JG.
Helicobacter pylori infection and high dietary salt independently induce atrophic gastritis and intestinal metaplasia in commercially available outbred Mongolian gerbils. Dig Dis Sci 2003;48:475–485.
53. Wang J, Xu L, Shi R, et al. Gastric atrophy and intestinal metaplasia before and after
Helicobacter pylori eradication: a meta-analysis. Digestion 2011;83:253–260.
54. Hwang YJ, Kim N, Lee HS, et al. Reversibility of atrophic gastritis and intestinal metaplasia after
Helicobacter pylori eradication - a prospective study for up to 10 years. Aliment Pharmacol Ther 2018;47:380–390.
55. Mera R, Fontham ET, Bravo LE, et al. Long term follow up of patients treated for
Helicobacter pylori infection. Gut 2005;54:1536–1540.
56. Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on
Helicobacter pylori eradication. Gut 2004;53:1244–1249.
57. Kong YJ, Yi HG, Dai JC, Wei MX. Histological changes of gastric mucosa after
Helicobacter pylori eradication: a systematic review and meta-analysis. World J Gastroenterol 2014;20:5903–5911.
58. Choi IJ, Kook MC, Kim YI, et al.
Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med 2018;378:1085–1095.
60. Zagari RM, Romano M, Ojetti V, et al. Guidelines for the management of
Helicobacter pylori infection in Italy: the III working group consensus report 2015. Dig Liver Dis 2015;47:903–912.
61. Malfertheiner P, Megraud F, O'morain CA, et al. Management of
Helicobacter pylori infection--the Maastricht IV/Florence consensus report. Gut 2012;61:646–664.